HIGH-LEVEL ENGRAFTMENT OF NOD SCID MICE BY PRIMITIVE NORMAL AND LEUKEMIC HEMATOPOIETIC-CELLS FROM PATIENTS WITH CHRONIC MYELOID-LEUKEMIA INCHRONIC PHASE/
Jcy. Wang et al., HIGH-LEVEL ENGRAFTMENT OF NOD SCID MICE BY PRIMITIVE NORMAL AND LEUKEMIC HEMATOPOIETIC-CELLS FROM PATIENTS WITH CHRONIC MYELOID-LEUKEMIA INCHRONIC PHASE/, Blood, 91(7), 1998, pp. 2406-2414
We have previously shown that intravenously injected peripheral blood
(PB) or bone marrow (BM) cells from newly diagnosed chronic myeloid le
ukemia (CML) patients can engraft the BM of sublethally irradiated sev
ere combined immunodeficient (SCID) mice. We now report engraftment re
sults for chronic phase CML cells in nonobese diabetic (NOD)/SCID reci
pients which show the superiority of this latter model. Transplantatio
n of NOD/SCID mice with 7 to 10 x 10(7) patient PB or BM cells resulte
d in the continuing presence of human cells in the BM of the mice for
up to 7 months, and primitive human CD34(+) cells, including those det
ectable as colony-forming cells (CFC), as long-term culture-initiating
cells, or by their coexpression of Thy-1, were found in a higher prop
ortion of the NOD/SCID recipients analyzed, and at higher levels than
were seen previously in SCID recipients. The human CFC and total human
cells present in the BM of the NOD/SCID mice transplanted with CML ce
lls also contained higher proportions of leukemic cells than were obta
ined in the SCID model, and NOD/SCID mice could be repopulated with tr
ansplants of enriched CD34(+) cells from patients with CML. These resu
lts suggest that the NOD/SCID mouse may allow greater engraftment and
amplification of both normal and leukemic (Ph+) cells sufficient for t
he quantitation and characterization of the normal and leukemic stem c
ells present in patients with CML. In addition, this model should make
practical the investigation of mechanisms underlying progression of t
he disease and the development of more effective in vivo therapies. (C
) 1998 by The American Society of Hematology.